Hepatocyte Senescence In Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)
Many people worldwide are affected by a common liver condition called metabolic dysfunction-associated steatotic liver disease, or MASLD. This disease involves an unhealthy buildup of fat in the liver and can worsen over time, potentially leading to severe scarring (fibrosis), liver failure, or even liver cancer. A significant factor contributing to this progression involves specialized liver cells, called hepatocytes, entering a state known as senescence.
Normally, hepatocytes perform vital functions for the liver. However, under stress, such as that experienced in MASLD, these cells can become “senescent.” This means they stop dividing and growing, but they don’t die. Instead, they remain active and start releasing a variety of harmful substances, collectively known as the Senescence-Associated Secretory Phenotype (SASP). These substances act like distress signals, triggering inflammation and promoting the formation of scar tissue in the liver, which further damages its function.
Beyond secreting harmful signals, senescent hepatocytes also disrupt the liver’s ability to process fats efficiently. They tend to take up more fat and struggle to break it down, leading to an increased accumulation of fat within the liver. Furthermore, the energy-producing parts of these cells, called mitochondria, can become dysfunctional, exacerbating the problem of fat buildup and overall liver impairment.
Understanding the role of these senescent liver cells is crucial because it opens up new avenues for treatment. Researchers are exploring ways to specifically target and remove these problematic cells, using drugs known as senolytics, which could potentially halt or even reverse the progression of MASLD and improve liver health.
Source: link to paper